SBIR/STTR Research Award
Discovery of new small molecule TLR4 agonists for the treatment of allergic rhinitis
Award amount
$41,693Program and phase
SBIR · Phase IIAward year
2019Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- DiaCarta, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- LY4NEL8B8FK9
- Solicitation number
- Not reported
- Topic code
- NIAID
Research abstract
This pilot study is aimed at judging the efficacy of the lead compound with a clinically relevant allergenThe relevant allergen chosen for this study is the house dust mite Dermatophagoides pteronyssinus allergenDer pLoToxTM Natural Der pfrom Indoor Biotechnologies with a low endotoxin contentEUgWe are selecting this allergen because our team has extensive prior experience with this allergen in mouse studies and has previously determined the doses required for sensitization and challengesAlternativelywe could also use the timothy grass allergen Phleum pratense allergenLoToxTM Recombinant Phl pfrom Indoor Biotechnologiesas a more relevant allergen for allergic rhinitisbut this would require additional dose response studies to determine the amounts of allergen required for both sensitization and challenges in the murine systemWe propose to investigate the efficacy of one versus two treatments of lead compoundtwo different dosesin the Der pallergen model
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Topic 345: RadTox - Measuring Radiation Toxicity using Circulating DNA
- IGF OT IGF PREDICTIVE BIOMARKERS OF ADVERSE REACTIONS TO RADIATION TREATMENT POP
- FGF-P to treat post-irradiation GI syndrome
- Novel Methods for Rapid Detection of Infection Agents and the Severity of Cellular Damage
- Novel Methods for Rapid Detection of Infection Agents and the Severity of Cellular Damage
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
Research funding history
6 SBIR/STTR records share this UEI (2008–2019). Reported award amounts total $3,784,405. Reported amounts are not federal obligations.
Phases: Phase II, Phase I
Agencies: Department of Health and Human Services, Department of Defense